4//SEC Filing
Hermans Kate 4
Accession 0001209191-23-005788
CIK 0001836056other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 6:07 PM ET
Size
17.0 KB
Accession
0001209191-23-005788
Insider Transaction Report
Form 4
Hermans Kate
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2023-01-27−210,000→ 0 totalExercise: $0.38Exp: 2032-06-29→ Ordinary Shares (210,000 underlying) - Award
Stock Option (right to buy)
2023-01-27+210,000→ 210,000 totalExercise: $0.28Exp: 2032-06-29→ Ordinary Shares (210,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-01-27−105,000→ 0 totalExercise: $0.43Exp: 2032-07-07→ Ordinary Shares (105,000 underlying) - Award
Stock Option (right to buy)
2023-01-27+105,000→ 105,000 totalExercise: $0.28Exp: 2032-07-07→ Ordinary Shares (105,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-01-27−210,000→ 0 totalExercise: $0.35From: 2022-12-15Exp: 2032-08-14→ Ordinary Shares (210,000 underlying) - Award
Stock Option (right to buy)
2023-01-27+210,000→ 210,000 totalExercise: $0.28From: 2022-12-15Exp: 2032-08-14→ Ordinary Shares (210,000 underlying)
Footnotes (4)
- [F1]The Ordinary Shares subject to the option vest in thirty-six equal monthly installments following June 30, 2022.
- [F2]The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer.
- [F3]The option held by the reporting person was amended to reduce the exercise price.
- [F4]The Ordinary Shares subject to the option will vest on the earlier of (i) July 8, 2023, or (ii) the day immediately prior to the date of the next Annual Grant Date as defined in the Company's Non-Employee Director Compensation Policy.
Documents
Issuer
Ambrx Biopharma Inc.
CIK 0001836056
Entity typeother
Related Parties
1- filerCIK 0001956523
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 6:07 PM ET
- Size
- 17.0 KB